Doral, FLNCT07869147Now EnrollingIRB Ready

Idiopathic Pulmonary Fibrosis Clinical Trial in Doral, FL

Access cutting-edge idiopathic pulmonary fibrosis treatment through this phase 2 clinical trial at a research site in Doral. Study-provided care at no cost to qualified participants.

Sponsored by Oorja Bio, Inc.

Quick Self-Assessment

See if you qualify for this Doral location

Preparing your pre-screening questions…

Expert Care in Doral

Access idiopathic pulmonary fibrosis specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related idiopathic pulmonary fibrosis treatment provided free

Apply for This Doral Location

Check if you qualify for this idiopathic pulmonary fibrosis clinical trial in Doral, FL

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Doral

    Convenient for FL residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Doral site if eligible
  4. 4Begin participation

About This Idiopathic Pulmonary Fibrosis Study in Doral

ORJ-001 is a new class of drugs intended for the treatment of patients with idiopathic pulmonary fibrosis (IPF). This is a Phase 2 study in two parts; the objective of Part A will determine if ORJ-001 is well-tolerated by patients and how long the drug stays in the body. Part B will test how well the drug affects lung function. Animal models of IPF have shown that ORJ-001 can repair damaged lung tissue and improve markers of lung function.

Sponsor: Oorja Bio, Inc.

Who Can Participate

Inclusion Criteria

Male or female participants aged ≥ 40 years when signing informed consent
Non-smoker or ex-smoker who has stopped smoking for \> 6 months prior to signing informed consent
Diagnosis of IPF, as defined by 2022 international guidelines and confirmed by centrally adjudicated finding of a definite or probable UIP pattern on HRCT of the chest. The HRCT may be performed at screening or, if available, a historical HRCT obtained within 12 months from screening may be submitted for central review
FVC of at least 45% of the predicted value and a DLCO, corrected for the hemoglobin level, of at least 25% and no greater than 90% of the predicted value. Note: Each test (FVC and DLCO) may be repeated once after a minimum of 24 hours if the initial result is deemed unreliable by the investigator
If receiving SOC antifibrotic therapy, participants must be on a stable regimen of a single approved therapy for at least 60 days prior to the screening visit. Participants who have discontinued SOC antifibrotic therapy due to tolerability or lack of response may be enrolled after at least 30 days of discontinuing the SOC antifibrotic therapy.
Negative serum pregnancy test in women of childbearing potential at the screening visit Key

Exclusion Criteria

Participants who are treatment-naïve with respect to SOC antifibrotic therapies
Women who are pregnant, nursing, or who plan to become pregnant while in the trial
Major surgery (including joint surgery) within 8 weeks from screening, or planned major surgery within 4 months following randomization
Presence of one or more significant concurrent medical conditions that may affect the outcome of the study per investigator judgement
Participants with relevant airway obstruction, defined as pre bronchodilator forced expiratory volume in 1 second (FEV1)/ forced vital capacity (FVC) ratio \< 0.7 at screening
Lower respiratory tract infection requiring antibiotics within 4 weeks from screening, or during the screening period (may be rescreened following recovery)
Acute IPF exacerbation within 3 months from screening, or during the screening period
Receiving more than 15 mg per day of prednisone during screening

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Doral?

Yes, this clinical trial (NCT07869147) has an active research site in Doral, FL that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Idiopathic Pulmonary Fibrosis Treatment Options in Doral, FL

If you're searching for idiopathic pulmonary fibrosis treatment options in Doral, FL, this clinical trial (NCT07869147) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Doral research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced idiopathic pulmonary fibrosis specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all idiopathic pulmonary fibrosis clinical trials near you to find additional studies recruiting in your area.

More Pulmonary Fibrosis Trials in Doral, FL

See all pulmonary fibrosis clinical trials recruiting in Doral — not just this study.

Browse Pulmonary Fibrosis Trials in Doral →

Browse More Trials by Condition

Pulmonary Fibrosis TrialsInterstitial Cystitis TrialsFibromyalgia TrialsInterstitial Lung Disease TrialsAll Conditions →

Ready to Join in Doral?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Doral, FL